Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Imunon, Inc. is a clinical-stage biotechnology company focused on developing DNA-based immunotherapies designed to stimulate a patient’s immune system to fight cancer and infectious diseases. The company operates within the biopharmaceutical and immuno-oncology industries, with its primary emphasis on localized cytokine delivery using non-viral DNA plasmid technology. Imunon does not currently generate product revenue and is primarily funded through equity financing and capital raises.
The company’s lead product candidate is IMNN-001, a DNA plasmid encoding interleukin-12 (IL‑12) formulated for intraperitoneal delivery in ovarian cancer patients. Imunon’s strategic positioning centers on improving the safety and effectiveness of cytokine-based immunotherapy by enabling local expression at the tumor site, reducing systemic toxicity. The company was originally founded in 1981 and operated for decades as Celsion Corporation, focusing on oncology drug delivery technologies before rebranding to Imunon, Inc. in 2023 to reflect its narrowed focus on DNA immunotherapy platforms.
Business Operations
Imunon’s operations are organized around a single reportable segment focused on immunotherapy research and development. Its core technology platform, TheraPlas, is a proprietary, non-viral DNA delivery system designed to enable targeted expression of therapeutic proteins within specific anatomical compartments. The company’s development efforts are primarily directed toward oncology indications, particularly gynecologic cancers.
The company’s lead clinical asset, IMNN-001, is being evaluated in combination with standard-of-care chemotherapy for advanced ovarian cancer. Imunon also maintains earlier-stage programs exploring infectious disease applications, including DNA-based vaccine approaches. Operations are conducted primarily in the United States, with clinical trials supported through external clinical research organizations. The company does not manufacture commercial products and relies on third-party vendors for clinical supply and trial execution.
Strategic Position & Investments
Imunon’s strategic direction is focused on advancing IMNN-001 through late-stage clinical development and validating its DNA immunotherapy platform in oncology. The company’s growth strategy prioritizes clinical milestone achievement, regulatory engagement, and potential future partnering opportunities rather than near-term commercialization.
Historically, Imunon has made strategic shifts rather than large acquisitions, including discontinuing its prior heat-activated liposomal chemotherapy program (ThermoDox) to concentrate resources on immunotherapy. The company does not report ownership of revenue-generating subsidiaries or a diversified investment portfolio. Its emerging technology focus remains on cytokine gene therapy, particularly localized IL‑12 expression, which represents a differentiated approach within the broader immuno-oncology landscape.
Geographic Footprint
Imunon is headquartered in Lawrenceville, New Jersey, and its operations are primarily based in the United States. The company’s clinical trials are conducted at multiple investigational sites, including U.S.-based academic and clinical research centers, with some international trial participation depending on study design.
While Imunon does not maintain commercial operations outside the U.S., its clinical development activities and regulatory strategy reflect an intention to support potential future approvals in North America and select international markets. The company does not currently report physical offices or subsidiaries outside the United States.
Leadership & Governance
Imunon is led by executives with experience in biotechnology development, clinical operations, and corporate finance, reflecting its focus as a development-stage company. The leadership team emphasizes capital discipline, clinical execution, and platform validation as core elements of its strategic vision.
Key executives include:
- Stéphane Gregoire – President and Chief Executive Officer
- Michael C. Mulholland – Chief Financial Officer
- Sophie Leong – Chief Operating Officer
- Leah M. Curtis – Vice President, Clinical Development
The company is governed by a board of directors with experience in biotechnology, oncology, and public company oversight, consistent with its status as a publicly traded clinical-stage biopharmaceutical company.